Evidence map›Paper›PMID 42115250›Full record

ArticleScientific reports2026

Triple-tracer PET (

Prathap Jayachandra Hosahalli, S P Somashekar, D N Bhoomika, B R Abhijit, Vishwanath Joshi, Prashanth Ramachandra Guthlu, Rajkumar Krishnappa, Mita Kumarswamy Kallur, Palak Wadhwa, K R Ashwin and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Prathap Jayachandra HosahalliDept of Nuclear Medicine, PET/CT & Theranostics, Aster Whitefield Hospital, Bangalore, India. drprathaphj@gmail.com.
S P SomashekarDept of Surgical Oncology, Aster Whitefield Hospital, Bangalore, India.
D N BhoomikaSenior Resident, Bangalore Medical College and Research Institute, Bangalore, India.
B R AbhijitDept of Medical Gastroenterologist, Aster Whitefield, Bangaluru, India.
Vishwanath JoshiDept of Radiology, Aster Whitefield Hospital, Bangalore, India.
Prashanth Ramachandra GuthluDept of Nuclear Medicine, HCG Hospitals, Bengaluru, India.
Rajkumar KrishnappaDept of Nuclear Medicine, HCG Hospitals, Bengaluru, India.
Mita Kumarswamy KallurDept of Nuclear Medicine, HCG Hospitals, Bengaluru, India.
Palak WadhwaUnited Imaging Healthcare, New Delhi, India.
K R AshwinDept of Surgical Oncology, Aster Whitefield Hospital, Bangalore, India.
C Rohit KumarDept of Surgical Oncology, Aster Whitefield Hospital, Bangalore, India.
Sai VivekDept of Medical Oncology, Aster Whitefield, Bangalore, India.
Suva LakshmiDept of Nuclear Medicine, PET/CT & Theranostics, Aster Whitefield Hospital, Bangalore, India.
Prajwal Rajaghatta KumaraswamyDepartment of General Surgery, Hassan Institute of Medical Sciences, Hassan, India.
B Shameer AhmedDept of Nuclear Medicine, PET/CT & Theranostics, Aster Whitefield Hospital, Bangalore, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This pilot study evaluated the diagnostic performance of a triple-tracer PET/CT protocol in 13 patients with advanced, high-grade neuroendocrine neoplasms (NENs; Ki-67 > 40%). NENs are characterized by biological heterogeneity and variable tracer avidity, complicating accurate staging and therapy selection. Each patient underwent imaging with [18F] FDG (metabolic activity), [68Ga] Ga-DOTANOC (somatostatin receptor expression), and [68Ga] Ga-FAPI-04 (fibroblast activation) within one week, enabling complementary biological assessment. A total of 92 metastatic lesions were analyzed (29 hepatic, 36 osseous, 27 nodal). In the liver, [18F] FDG demonstrated the highest uptake (SUV

Indexed as

Fluorodeoxyglucose F18Neuroendocrine TumorsOrganometallic CompoundsPositron Emission Tomography Computed TomographyAdultAgedFemaleFibroblast Activation Protein AlphaGallium RadioisotopesHumansMaleMiddle AgedNeoplasm GradingNeoplasm MetastasisPilot ProjectsQuinolines68Ga-DOTANOC68Ga-FAPIFibroblast Activation Protein AlphaFluorodeoxyglucose F18Gallium RadioisotopesOrganometallic CompoundsQuinolinesRadiopharmaceuticalsDOTANOCFAPIFDG PET/CTHigh-grade NENNeuroendocrine neoplasmsRadioligand cocktail therapyStromaTheranosticsTumor heterogeneity

Identifiers

PMID42115250
PMCPMC13351023

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.